{"success":true,"data":{"pressRelease":{"id":"53007","rtpr_id":"nACSPKs16a","ticker":"ONCO","exchange":"","all_tickers":["ONCO"],"title":"Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program","author":"ACCESSWIRE","published_at":"2026-06-02T22:00:00.721Z","article_body":"Also Announces Marketing Program\n\nVANCOUVER, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 2,\n2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)\n(WKN: A3EKSZ) (\"Onco\" or the \"Company\") announces, further to its news release\ndated May 19, 2026, the successful advancement of kilogram-scale manufacturing\nactivities for the B4 precursor component supporting the development of\nONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase\nPhosphatase (PNKP) Inhibitor Technology.\n\nThe milestone was achieved through the Company's ongoing chemistry,\nmanufacturing and controls (CMC) collaboration with Dalton Pharma Services and\nrepresents an important step in scaling the manufacturing process required to\nsupport future formulation development, engineering batches, GMP production\nand planned clinical studies.\n\nB4 is a critical precursor used in the synthesis pathway for ONC010 and forms\nan essential component of the Company's broader manufacturing strategy. Recent\nscale-up activities resulted in the successful production and isolation of\napproximately 952 grams of B4 material, representing a meaningful increase in\nmanufacturing scale while maintaining quality standards necessary for\ncontinued development activities.\n\nThe Company believes this achievement further validates the scalability of its\nmanufacturing approach and supports ongoing efforts to establish a robust and\nreproducible production process for future clinical supply.\n\n\"This milestone represents another important advancement in the maturation of\nour ONC010 manufacturing platform. Successfully scaling the production of key\nprecursor materials is essential to building a reliable and scalable supply\nchain capable of supporting future clinical development. The continued\nprogress achieved by our manufacturing partners demonstrates the strength of\nour integrated development strategy and reinforces our commitment to advancing\nONC010 toward the clinic,\" said Thomas O'Shaughnessy, Chief Executive Officer\nof Onco-Innovations.\n\nThe B4 scale-up milestone forms part of a broader integrated manufacturing\nprogram that includes precursor synthesis, Active Pharmaceutical Ingredient\n(API) production, polymer development, nanoparticle formulation, analytical\ncharacterization and future GMP manufacturing activities. The Company's\nmanufacturing ecosystem currently includes Dalton Pharma Services and\nNucro-Technics, each contributing specialized expertise across critical\ndevelopment workstreams.\n\n\"Manufacturing readiness is a fundamental component of successful clinical\ntranslation. The advancement of kilogram-scale precursor production\nstrengthens the foundation of the ONC010 program and supports the Company's\nbroader objective of delivering a clinically viable and scalable therapeutic\ncandidate. As we continue progressing through IND-enabling activities, these\nmanufacturing achievements contribute directly to reducing development risk\nand supporting future regulatory readiness,\" stated Dr. Islam Mohamed, Chief\nMedical Officer of Onco-Innovations.\n\nThe Company also announces that it has engaged InvestorBrandNetwork (\"IBN\")\n(business address: 1108 Lavaca Street, Suite 110-IBN, Austin, TX 78701;\ntelephone: 512-354-7000; website: www.IBN.ai; contact email: Dutch@IBN.fm), an\narm's length third-party, to provide market awareness, corporate\ncommunications and digital media services, including editorial content, press\nrelease recap-style coverage, newsletter coverage, social media relations\nsupport, podcast-related distribution and syndication through IBN's\ninvestor-focused media network (the \"Services\"). The Company will pay IBN an\naggregate cash fee of USD $76,500 for the Services (the \"Consideration\"). The\nCompany also announces that it has obtained the return of an unused balance of\nUSD $80,000 from its prior market awareness engagement with another provider\n(see Company press release dated May 1, 2026). The Company intends to allocate\nthe returned unused balance toward the Consideration. The Services are\nscheduled to run until September 30, 2026, or budget exhaustion, and is\nstructured to allow for ongoing evaluation and, accordingly, may be shortened\nor extended at the discretion of the Company. No securities have been provided\nto IBN or its principals as compensation for the Services.\n\nAbout ONC010\n\nONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase\nPhosphatase (PNKP), a key DNA damage repair enzyme. The program is being\ndeveloped to exploit vulnerabilities in cancer cells dependent on DNA repair\npathways and is intended to provide a differentiated therapeutic approach for\npatients with difficult-to-treat malignancies.\n\nAbout Onco-Innovations Limited\n\nOnco-Innovations is a Canadian-based company dedicated to cancer research and\ntreatment, specializing in oncology. Onco's mission is to pursue the\nprevention and treatment of cancer through pioneering research and innovative\nsolutions. The Company has secured an exclusive worldwide license to patented\ntechnology that targets solid tumours.\n\nON BEHALF OF ONCO-INNOVATIONS LIMITED,\n\n\"Thomas O'Shaughnessy\"\nChief Executive Officer\n\nFor more information, please contact:\n\nThomas O'Shaughnessy\nChief Executive Officer\nTel: + 1 888 261 8055\ninvestors@oncoinnovations.com\n\nForward-Looking Statements Caution. This news release contains forward-looking\nstatements, including in relation to the Company's research and development\nplans, business and plans generally, and other statements that are not\nhistorical facts. Forward-looking statements are often identified by terms\nsuch as \"will\", \"may\", \"potential\", \"should\", \"anticipate\", \"expects\" and\nsimilar expressions. All statements other than statements of historical fact,\nincluded in this release are forward-looking statements that involve risks and\nuncertainties. There can be no assurance that such statements will prove to be\naccurate and actual results and future events could differ materially from\nthose anticipated in such statements. The reader is cautioned that assumptions\nused in the preparation of any forward-looking information may prove to be\nincorrect. Events or circumstances may cause actual results to differ\nmaterially from those predicted, as a result of numerous known and unknown\nrisks, uncertainties, and other factors, many of which are beyond the control\nof the Company. In particular, the Company may not be able to carry out its\nresearch and development plans for a variety of reasons, including, but not\nlimited to, the failure to receive regulatory approvals, the failure to\nmaintain contractual relations and the failure to obtain financing and retain\nkey personnel. The reader is cautioned not to place undue reliance on any\nforward-looking information. Such information, although considered reasonable\nby management at the time of preparation, may prove to be incorrect and actual\nresults may differ materially from those anticipated. Forward-looking\nstatements contained in this news release are expressly qualified by this\ncautionary statement. The forward-looking statements contained in this news\nrelease are made as of the date of this news release and the Company will\nupdate or revise publicly any of the included forward-looking statements as\nexpressly required by applicable law.\n\nSOURCE: Onco-Innovations Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-advances-1kg-scale-up-of-b4-precursor-supporting-onc-1172868)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSPKs16a","title":"Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program","author":"ACCESSWIRE","ticker":"ONCO","created":"2026-06-02T22:00:00.721Z","tickers":["ONCO"],"exchange":"","article_body":"Also Announces Marketing Program\n\nVANCOUVER, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 2,\n2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)\n(WKN: A3EKSZ) (\"Onco\" or the \"Company\") announces, further to its news release\ndated May 19, 2026, the successful advancement of kilogram-scale manufacturing\nactivities for the B4 precursor component supporting the development of\nONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase\nPhosphatase (PNKP) Inhibitor Technology.\n\nThe milestone was achieved through the Company's ongoing chemistry,\nmanufacturing and controls (CMC) collaboration with Dalton Pharma Services and\nrepresents an important step in scaling the manufacturing process required to\nsupport future formulation development, engineering batches, GMP production\nand planned clinical studies.\n\nB4 is a critical precursor used in the synthesis pathway for ONC010 and forms\nan essential component of the Company's broader manufacturing strategy. Recent\nscale-up activities resulted in the successful production and isolation of\napproximately 952 grams of B4 material, representing a meaningful increase in\nmanufacturing scale while maintaining quality standards necessary for\ncontinued development activities.\n\nThe Company believes this achievement further validates the scalability of its\nmanufacturing approach and supports ongoing efforts to establish a robust and\nreproducible production process for future clinical supply.\n\n\"This milestone represents another important advancement in the maturation of\nour ONC010 manufacturing platform. Successfully scaling the production of key\nprecursor materials is essential to building a reliable and scalable supply\nchain capable of supporting future clinical development. The continued\nprogress achieved by our manufacturing partners demonstrates the strength of\nour integrated development strategy and reinforces our commitment to advancing\nONC010 toward the clinic,\" said Thomas O'Shaughnessy, Chief Executive Officer\nof Onco-Innovations.\n\nThe B4 scale-up milestone forms part of a broader integrated manufacturing\nprogram that includes precursor synthesis, Active Pharmaceutical Ingredient\n(API) production, polymer development, nanoparticle formulation, analytical\ncharacterization and future GMP manufacturing activities. The Company's\nmanufacturing ecosystem currently includes Dalton Pharma Services and\nNucro-Technics, each contributing specialized expertise across critical\ndevelopment workstreams.\n\n\"Manufacturing readiness is a fundamental component of successful clinical\ntranslation. The advancement of kilogram-scale precursor production\nstrengthens the foundation of the ONC010 program and supports the Company's\nbroader objective of delivering a clinically viable and scalable therapeutic\ncandidate. As we continue progressing through IND-enabling activities, these\nmanufacturing achievements contribute directly to reducing development risk\nand supporting future regulatory readiness,\" stated Dr. Islam Mohamed, Chief\nMedical Officer of Onco-Innovations.\n\nThe Company also announces that it has engaged InvestorBrandNetwork (\"IBN\")\n(business address: 1108 Lavaca Street, Suite 110-IBN, Austin, TX 78701;\ntelephone: 512-354-7000; website: www.IBN.ai; contact email: Dutch@IBN.fm), an\narm's length third-party, to provide market awareness, corporate\ncommunications and digital media services, including editorial content, press\nrelease recap-style coverage, newsletter coverage, social media relations\nsupport, podcast-related distribution and syndication through IBN's\ninvestor-focused media network (the \"Services\"). The Company will pay IBN an\naggregate cash fee of USD $76,500 for the Services (the \"Consideration\"). The\nCompany also announces that it has obtained the return of an unused balance of\nUSD $80,000 from its prior market awareness engagement with another provider\n(see Company press release dated May 1, 2026). The Company intends to allocate\nthe returned unused balance toward the Consideration. The Services are\nscheduled to run until September 30, 2026, or budget exhaustion, and is\nstructured to allow for ongoing evaluation and, accordingly, may be shortened\nor extended at the discretion of the Company. No securities have been provided\nto IBN or its principals as compensation for the Services.\n\nAbout ONC010\n\nONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase\nPhosphatase (PNKP), a key DNA damage repair enzyme. The program is being\ndeveloped to exploit vulnerabilities in cancer cells dependent on DNA repair\npathways and is intended to provide a differentiated therapeutic approach for\npatients with difficult-to-treat malignancies.\n\nAbout Onco-Innovations Limited\n\nOnco-Innovations is a Canadian-based company dedicated to cancer research and\ntreatment, specializing in oncology. Onco's mission is to pursue the\nprevention and treatment of cancer through pioneering research and innovative\nsolutions. The Company has secured an exclusive worldwide license to patented\ntechnology that targets solid tumours.\n\nON BEHALF OF ONCO-INNOVATIONS LIMITED,\n\n\"Thomas O'Shaughnessy\"\nChief Executive Officer\n\nFor more information, please contact:\n\nThomas O'Shaughnessy\nChief Executive Officer\nTel: + 1 888 261 8055\ninvestors@oncoinnovations.com\n\nForward-Looking Statements Caution. This news release contains forward-looking\nstatements, including in relation to the Company's research and development\nplans, business and plans generally, and other statements that are not\nhistorical facts. Forward-looking statements are often identified by terms\nsuch as \"will\", \"may\", \"potential\", \"should\", \"anticipate\", \"expects\" and\nsimilar expressions. All statements other than statements of historical fact,\nincluded in this release are forward-looking statements that involve risks and\nuncertainties. There can be no assurance that such statements will prove to be\naccurate and actual results and future events could differ materially from\nthose anticipated in such statements. The reader is cautioned that assumptions\nused in the preparation of any forward-looking information may prove to be\nincorrect. Events or circumstances may cause actual results to differ\nmaterially from those predicted, as a result of numerous known and unknown\nrisks, uncertainties, and other factors, many of which are beyond the control\nof the Company. In particular, the Company may not be able to carry out its\nresearch and development plans for a variety of reasons, including, but not\nlimited to, the failure to receive regulatory approvals, the failure to\nmaintain contractual relations and the failure to obtain financing and retain\nkey personnel. The reader is cautioned not to place undue reliance on any\nforward-looking information. Such information, although considered reasonable\nby management at the time of preparation, may prove to be incorrect and actual\nresults may differ materially from those anticipated. Forward-looking\nstatements contained in this news release are expressly qualified by this\ncautionary statement. The forward-looking statements contained in this news\nrelease are made as of the date of this news release and the Company will\nupdate or revise publicly any of the included forward-looking statements as\nexpressly required by applicable law.\n\nSOURCE: Onco-Innovations Limited\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-advances-1kg-scale-up-of-b4-precursor-supporting-onc-1172868)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-02T22:00:00.78005754Z","server_sent_at_ms":1780437600780},"received_at":"2026-06-02T22:00:00.881Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/onco-innovations-advances-1kg-scale-up-of-b4-precursor-supporting-onc-1172868"},"analysis":{"id":"42439","press_release_id":"53007","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Onco-Innovations successfully scaled the manufacturing of its B4 precursor to approximately 952 grams, a critical step for producing its lead asset ONC010.\n\nThe milestone, achieved in collaboration with Dalton Pharma Services, validates the scalability of the CMC process and supports future GMP production and clinical studies.\n\nThe company also engaged InvestorBrandNetwork for marketing services, funding the $76,500 fee largely through an $80,000 refund from a prior provider.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"CMC de-risking for ONC010: 1kg precursor scale-up achieved, supporting IND-enabling activities."},"keyFigures":{"drugName":"ONC010","customDimensions":{"ibn_service_fee_usd":76500,"b4_precursor_yield_grams":952,"prior_provider_refund_usd":80000}},"quotedText":"Successfully scaling the production of key precursor materials is essential to building a reliable and scalable supply chain capable of supporting future clinical development.","namedEntities":{"people":[{"name":"Thomas O'Shaughnessy","role":"Chief Executive Officer"},{"name":"Dr. Islam Mohamed","role":"Chief Medical Officer"}],"products":["ONC010","B4 precursor"],"companies":[{"name":"Onco-Innovations Limited","ticker":"ONCO","relationship":"filer"},{"name":"Dalton Pharma Services","relationship":"CMC partner"},{"name":"Nucro-Technics","relationship":"manufacturing partner"},{"name":"InvestorBrandNetwork","relationship":"marketing services provider"}],"dollarAmounts":[{"amount":"USD $76,500","context":"fee for InvestorBrandNetwork services"},{"amount":"USD $80,000","context":"refund from prior market awareness provider"}]},"materialImpact":{"score":3,"reasoning":"Successful kilogram-scale manufacturing of a critical precursor (B4) for the lead asset ONC010 is a positive de-risking milestone for CMC and future clinical supply. It supports IND-enabling activities but is not a clinical data readout or regulatory approval."},"tickerRelevance":{"others":[],"primary":"ONCO"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"cmc_milestone","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Onco-Innovations successfully scaled the manufacturing of its B4 precursor to approximately 952 grams, a critical step for producing its lead asset ONC010.\n\nThe milestone, achieved in collaboration with Dalton Pharma Services, validates the scalability of the CMC process and supports future GMP production and clinical studies.\n\nThe company also engaged InvestorBrandNetwork for marketing services, funding the $76,500 fee largely through an $80,000 refund from a prior provider.","key_figures":{"drugName":"ONC010","customDimensions":{"ibn_service_fee_usd":76500,"b4_precursor_yield_grams":952,"prior_provider_refund_usd":80000}},"named_entities":{"people":[{"name":"Thomas O'Shaughnessy","role":"Chief Executive Officer"},{"name":"Dr. Islam Mohamed","role":"Chief Medical Officer"}],"products":["ONC010","B4 precursor"],"companies":[{"name":"Onco-Innovations Limited","ticker":"ONCO","relationship":"filer"},{"name":"Dalton Pharma Services","relationship":"CMC partner"},{"name":"Nucro-Technics","relationship":"manufacturing partner"},{"name":"InvestorBrandNetwork","relationship":"marketing services provider"}],"dollarAmounts":[{"amount":"USD $76,500","context":"fee for InvestorBrandNetwork services"},{"amount":"USD $80,000","context":"refund from prior market awareness provider"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T22:01:57.789Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"cmc_milestone","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":51177,"modelName":"george-droid-qwen-72b"}}